High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study.
Journal
Journal of global oncology
ISSN: 2378-9506
Titre abrégé: J Glob Oncol
Pays: United States
ID NLM: 101674751
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
28
7
2020
Statut:
ppublish
Résumé
BRAF mutation in papillary thyroid carcinoma (PTC) is associated with an aggressive phenotype, with varying incidence. We evaluated the prevalence of BRAF mutations in PTC among Filipino patients and their correlation with clinicopathologic characteristics. Clinicopathologic data were retrieved from 64 sequential patients who underwent thyroidectomy from June 2016 to December 2016. BRAF mutation testing was performed using Sanger sequencing. Eighteen (28%) of 64 patients were diagnosed with PTC; 12 (70.59%) of 17 harbored a BRAF V600E mutation (no amplification in one patient). Demographics of patients with PTC were as follows: 13 women and five men, with median age of 46 years (range, 25 to 74 years). Fourteen patients had conventional subtype PTC; two, follicular variant; one, oncocytic variant; and one, tall-cell features. Tumor size ranged from 0.8 to 7.0 cm (median, 2.4 cm); extrathyroidal extension was present in seven (38.9%) of 18 patients, multifocality in six (33.33%) of eight, and lymph node involvement in eight (44.4%) of 18. Significant association between presence of a BRAF mutation and presence of extrathyroidal extension or lymph node involvement was not determined due to the limited sample size. The high preponderance of BRAF mutation (70.59%) suggests some correlation with the previously reported lower 5-year survival among Filipinos. This warrants further investigation in a larger-cohort prospective study.
Identifiants
pubmed: 30694737
doi: 10.1200/JGO.18.00085
pmc: PMC6426509
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Références
Oncogene. 2004 Sep 23;23(44):7436-40
pubmed: 15273715
Oncogene. 2005 Oct 6;24(44):6646-56
pubmed: 16007166
Eur J Endocrinol. 2006 Feb;154(2):341-8
pubmed: 16452550
J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90
pubmed: 17785355
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Endocr Relat Cancer. 2014;21(6):891-902
pubmed: 25266729
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Arch Pathol Lab Med. 2016 Feb;140(2):134-9
pubmed: 26910217
Malays J Pathol. 2016 Aug;38(2):141-8
pubmed: 27568671
Oncotarget. 2017 Feb 7;8(6):10637-10649
pubmed: 27793009
Cancer Res Treat. 2017 Oct;49(4):906-914
pubmed: 28052655
Mol Cell Endocrinol. 2018 Sep 5;472:140-148
pubmed: 29229408